ReviewPsychopharmacology2004
From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes.
Review in Psychopharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 58 citations in OpenAlex.
- 5-HTP inhibits eosinophilia via intracellular endothelial 5-HTRs; SNPs in 5-HTRs associate with asthmatic lung function.Frontiers in allergy · 2024Article
- Association of TPH1 and serotonin transporter genotypes with treatment response for suicidal ideation: a preliminary study.European archives of psychiatry and clinical neuroscience · 2020Article
- Therapeutic Duration and Extent Affect the Effect of Moxibustion on Depression-Like Behaviour in Rats via Regulating the Brain Tryptophan Transport and Metabolism.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Article
- Genetic polymorphism in the serotonin transporter gene-linked polymorphic region and response to serotonin reuptake inhibitors in patients with premature ejaculation.Clinics (Sao Paulo, Brazil) · 2014Article
- Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophan.American journal of physiology. Lung cellular and molecular physiology · 2012Article
- HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort.Neuromolecular medicine · 2010Article
- Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets.Biochimica et biophysica acta · 2007Review
- Heterotrimeric g proteins: insights into the neurobiology of mood disorders.Current neuropharmacology · 2006Article
- Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2005Article
- Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.Psychopharmacology · 2005Article
- Pharmacogenetics in mood disorder.Current opinion in psychiatry · 2005Article
- Pharmacogenomics in depression and antidepressants.Dialogues in clinical neuroscience · 2005Review
- Ethical problems in pharmacogenetic studies of psychiatric disorders.The pharmacogenomics journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetic studies in mood disorders are raising increasing interest, after the first findings of a significant association between antidepressant response and a functional polymorphism in the upstream regulatory region of the serotonin transporter gene (SERTPR). However, the results of published studies are not unequivocal. The reasons of these discordances could be various: the small samples, which could affect the power to detect a good effect size, the use of different and often not comparable scales and methodologies to assess the response rates. Notwithstanding all these limitations, the choice of candidate genes involved in antidepressant response is one of the crucial steps to target future research. In the present paper, we reviewed the literature concerning pharmacogenetic studies on antidepressant response. This analysis evidenced a number of studies consistently confirming the association of the SERTPR short variant with a poorer response to antidepressants, at least for the Caucasian samples. Further unreplicated positive findings included tryptophan hydroxylase (TPH), G-protein beta(3)-subunit (Gbeta(3)) and serotonin receptor 2A gene polymorphisms. Through the review, we also suggested possible candidate genes for future studies, which are involved in the main monoaminergic neurotransmitters pathways (norepinephrine, dopamine, serotonin), in substance P, neurokinines and glutamate systems, in the intracellular signal transduction pathway, in the phosphorylation process and in the control of the transcriptional activity system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.